20-072 - Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
Status: openDouble Blind Randomized Phase II Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients with Respiratory Failure
Treatment for Respiratory Failure
Description
To assess the safety and efficacy of Pulmozyme® in patients with respiratory failure from COVID-19 positive patients who are in respiratory failure.
Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at (251) 445-9834 or by email at wlblount@health.southalabama.edu.
Providers Associated With This Trial
Principle Investigator
![Jon Simmons]()
View ProfileJon D. Simmons, M.D., F.A.C.S.Trauma/Emergency General SurgeonTrauma Medical Director; Chief of Trauma & Acute Care Surgery
Sub Investigators
![Karen Fagan]()
View ProfileKaren A. Fagan, M.D.PulmonologistDirector of Division Pulmonary & Critical Care; Director of Pulmonary Hypertension Center; Professor of Internal Medicine![Errol Crook]()
View ProfileErrol D. Crook, M.D.NephrologistDirector of Center for Healthy Communities; Professor and Abraham Mitchell Chair of Internal Medicine
This link will open in a new tab or window.